martes, 26 de mayo de 2015

National Guideline Clearinghouse | American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

full-text ►

National Guideline Clearinghouse | American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.



American Gastroenterological Association Institute

National Guideline Clearinghouse (NGC)

Guideline Title
American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
Bibliographic Source(s)
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):215-9. [4 references] PubMed External Web Site Policy
Guideline Status
This is the current release of the guideline.
This guideline meets NGC's 2013 (revised) inclusion criteria.
.-.-.



American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppres... - PubMed - NCBI





 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Erratum in

  • Gastroenterology. 2015 Feb;148(2):455. multiple investigator names added.

PMID:
 
25447850
 
[PubMed - indexed for MEDLINE]

No hay comentarios:

Publicar un comentario